Literature DB >> 22505699

Interleukin 6 in systemic sclerosis and potential implications for targeted therapy.

Chayawee Muangchan1, Janet E Pope.   

Abstract

OBJECTIVE: The purpose of this study was to review the potential importance of interleukin 6 (IL-6) in systemic sclerosis (SSc).
METHODS: PubMed and Scopus databases and American College of Rheumatology (from 2009-10) and European League Against Rheumatism abstracts (2009-11) were searched using keywords "scleroderma; SSc; cytokines; interleukins; interleukin 6" and publications were excluded if not pertaining to IL-6 in SSc. Data were extracted from selected articles to construct a cell interaction model of the effects of IL-6 in SSc.
RESULTS: A total of 416 reports were found (PubMed, n = 82; Scopus, n = 331; 3 abstracts); 372 were excluded (irrelevant) leaving 41 publications and 3 abstracts (39 from PubMed, 18 from Scopus; but 16 were repeated from PubMed search), where 40 suggested IL-6 was important in SSc and 4 did not. Effects of IL-6 in SSc were summarized schematically.
CONCLUSION: Of the 44 publications, 40 suggested that IL-6 may be important in SSc, allowing for a conceptual framework within SSc including effects on macrophages, fibroblasts, plasma cells, monocytes, and extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505699     DOI: 10.3899/jrheum.111423

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

2.  Mandibular resorption and vocal cord paralysis: a catastrophic form of systemic sclerosis.

Authors:  Pedro Mendonça; Anna Viola Taulaigo; Antonio Caetano; Maria Francisca Moraes-Fontes
Journal:  BMJ Case Rep       Date:  2019-02-28

Review 3.  Systemic sclerosis phase III clinical trials: Hope on the horizon?

Authors:  Martin Aringer; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2018-05-28

4.  Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature.

Authors:  Hiroki Wakabayashi; Hitoshi Kino; Makoto Kondo; Keiichi Yamanaka; Masahiro Hasegawa; Akihiro Sudo
Journal:  BMC Rheumatol       Date:  2019-04-24

Review 5.  An update on stem cell transplantation in autoimmune rheumatologic disorders.

Authors:  Sheryl Mascarenhas; Belinda Avalos; Stacy P Ardoin
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 6.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

Review 7.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

8.  Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts.

Authors:  Luigi Di Luigi; Paolo Sgrò; Guglielmo Duranti; Stefania Sabatini; Daniela Caporossi; Francesco Del Galdo; Ivan Dimauro; Cristina Antinozzi
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

9.  Mechanistic insight into the norepinephrine-induced fibrosis in systemic sclerosis.

Authors:  Akihito Uehara; Sei-Ichiro Motegi; Kazuya Yamada; Akihiko Uchiyama; Buddhini Perera; Sayaka Toki; Sachiko Ogino; Yoko Yokoyama; Yuko Takeuchi; Osamu Ishikawa
Journal:  Sci Rep       Date:  2016-09-21       Impact factor: 4.379

10.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Authors:  Dinesh Khanna; Christopher P Denton; Celia J F Lin; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Helen Spotswood; Laura Burke; Jeffrey Siegel; Angelika Jahreis; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2017-10-24       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.